ST PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86,400 KRW | -2.48% |
|
+3.72% | +27.43% |
| 2023 | ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2021 | ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility | CI |
| Sales 2024 * | 323B 235M | Sales 2025 * | 375B 273M | Capitalization | 1,636B 1.19B |
|---|---|---|---|---|---|
| Net income 2024 * | 38B 27.63M | Net income 2025 * | 59B 42.89M | EV / Sales 2024 * | 5.44 x |
| Net Debt 2024 * | 123B 89.33M | Net Debt 2025 * | 102B 73.9M | EV / Sales 2025 * | 4.63 x |
| P/E ratio 2024 * |
41.7
x | P/E ratio 2025 * |
27.5
x | Employees | 645 |
| Yield 2024 * |
0.58% | Yield 2025 * |
0.58% | Free-Float | 53.31% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.48% | ||
| 1 week | +3.72% | ||
| Current month | -2.70% | ||
| 1 month | -6.19% | ||
| 3 months | +41.18% | ||
| 6 months | +25.04% | ||
| Current year | +27.43% |
1 week
83 000.00
89 000.00
1 month
76 400.0093 800.00
Current year
59 900.0099 000.00
1 year
59 900.0099 000.00
3 years
59 900.00150 800.00
5 years
12 300.00150 800.00
10 years
12 300.00150 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gyeong-Jin Kim
CEO | Chief Executive Officer | 61 | 17-03-16 |
Kyung-Eun Jung
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Hyun-Min Lee
BRD | Director/Board Member | 51 | 19-03-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gyeong-Jin Kim
CEO | Chief Executive Officer | 61 | 17-03-16 |
Hyeong-Jun An
BRD | Director/Board Member | 60 | 18-03-15 |
Hyun-Min Lee
BRD | Director/Board Member | 51 | 19-03-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +1.38% | - | |
| 0.00% | 117 M€ | +0.16% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 85,700 | -0.81% | 73,342 |
| 24-04-25 | 86,400 | -2.48% | 79,024 |
| 24-04-24 | 88,600 | +1.03% | 167,929 |
| 24-04-23 | 87,700 | +3.91% | 170,966 |
| 24-04-22 | 84,400 | +2.68% | 246,296 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
86,400
KRW
Average target price
105,556
KRW
Spread / Average Target
+22.17%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +27.43% | 1.19B | |
| +24.29% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.11% | 233B | |
| +5.51% | 201B | |
| -10.10% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- A237690 Stock
